Spectrum Pharmaceuticals (NasdaqGS: SPPI), a
biotechnology company with fully integrated commercial and drug
development operations with a primary focus in Hematology and
Oncology, will be hosting its fourth quarter 2014 financial results
and analyst day in New York City on Friday, March 13, 2015 from
10:00 a.m. to 12:00 p.m. ET.
Spectrum’s management and external experts will provide an
update on the Company's business and discuss the Company’s
development portfolio.
Spectrum speakers scheduled to present include:
Rajesh Shrotriya, M.D., Chairman of the Board and Chief
Executive OfficerJoseph Turgeon, President and Chief Operating
OfficerKurt Gustafson, Executive Vice President, Chief Financial
Officer and Principal Accounting OfficerLee Allen, M.D., Chief
Medical OfficerTom Riga, Senior Vice President and Chief Commercial
Officer
Four external key opinion leaders scheduled to present
include:
Francisco Esteva, M.D., PhDProfessor of Medicine, Director,
Breast Medical Oncology Associate, Director of Clinical
Investigation, Laura and Isaac Perlmutter Cancer Center New York
University Langone Medical Center.
Parameswaran Hari, M.D., MRCP, MSArmand J. Quick/William F.
Stapp Professor of Hematology at the Medical College of Wisconsin,
Director of the Adult Blood and Marrow Transplant Program at
Froedtert Hospital and the Section Head of Hematologic Malignancies
and Transplantation, in the Division of Hematology and Oncology in
the Department of Medicine.
Jeffrey L. Vacirca, M.D., FACPCEO, Managing Partner & Chief
of Clinical Research at North Shore Hematology/Oncology Associates
Medical Director for ION/ASBSG Vice-President, Community Oncology
Alliance CEO & President National Translational Research
Group.
Prof Dr. JA Witjes, M.D., PhDStaff Member in the Department of
Urology, The Radboud University Nijmegen Medical
Center, Member of the Faculty of the European School of
Urology and Chair of the Dutch Guidelines Committee on Bladder
Cancer and the EAU Guidelines Committee on Metastatic and
Muscle-Invasive Bladder Cancer.
Conference Call
Friday, March 13, 2015 @ 10:00 a.m.
Eastern/7:00 a.m. Pacific
Domestic:
(877) 837-3910, Conference ID#
82077760
International:
(973) 796-5077, Conference ID#
82077760
For interested individuals unable to join the call, a replay
will be available from March 13, 2015 @ 2:00 p.m.
ET/11:00 a.m. PT through March 26, 2015 until 11:59
p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In #:
(855) 859-2056, Conference ID#
82077760
International Replay Dial-In #:
(404) 537-3406, Conference ID#
82077760
This conference call will also be webcast. Listeners may access
the webcast, which will be available on the investor relations page
of Spectrum
Pharmaceuticals' website: www.sppirx.com on March
13, 2015 at 10:00 a.m. Eastern/7:00
a.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in oncology and hematology. Spectrum
and its affiliates market five oncology drugs─ FUSILEV®
(levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate
injection), also marketed in the U.S.; ZEVALIN® (ibritumomab
tiuxetan) Injection for intravenous use, for which the Company has
worldwide marketing rights; MARQIBO® (vinCRIStine sulfate LIPOSOME
injection) for intravenous infusion, for which the Company has
worldwide marketing rights and BELEODAQ® (belinostat) for Injection
in the U.S.. Spectrum's strong track record in in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available at
www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify,
acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the
expertise of partners and employees around the world to assist us
in the execution of our strategy, and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that our existing and new drug candidates may not prove safe or
effective, the possibility that our existing and new applications
to the FDA and other regulatory agencies may not receive approval
in a timely manner or at all, the possibility that our existing and
new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that
our efforts to acquire or in-license and develop additional drug
candidates may fail, our lack of sustained revenue history, our
limited marketing experience, our dependence on third parties for
clinical trials, manufacturing, distribution and quality control
and other risks that are described in further detail in the
Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®,
MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum
Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™
and the Spectrum Pharmaceuticals logos are trademarks owned by
Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved
Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President,
Strategic Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024